The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats. Rats made nephrotic exhibited severe hyperlipidemia with increases in all major lipoprotein fractions. Probucol treatment of nephrotic rats significantly lowered plasma triglyceride (TG), cholesterol (Ch) phospholipid (PL) and apoprotein B associated with very-low-density and low-density lipoprotein and Ch and PL in high-density lipoprotein (HDL). Malondialdehyde (MDA) associated with the lipoproteins was significantly elevated in nephrotic rats and probucol treatment also lowered MDA concentration in all major lipoproteins. In control rats probucol moderately, but significantly, reduced plasma TG and HDL-Ch concentrations. Proteinuria associated with nephrosis was decreased significantly by treatment with probucol. Probucol treatment did not affect blood urea nitrogen and plasma creatinine levels. A significant positive correlation existed between the amount of protein excreted in urine and the plasma lipid concentrations in all nephrotic rats, suggesting that the hypolipidemic effect of probucol may attenuate proteinuria associated with nephrosis. These results suggest that probucol may be a favorable treatment for hyperlipidemia associated with nephrotic syndrome.
Hirano
T
T
Department of Internal Medicine, Itabashi Central General Hospital, Tokyo, Japan.
Mamo
J C
JC
Nagano
S
S
Sugisaki
T
T
D000818:Animals; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000209:etiology; D006951:Hyperlipoproteinemias / Q000188:drug therapy / Q000209:etiology; D007668:Kidney / Q000187:drug effects; D008297:Male; D009404:Nephrotic Syndrome / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D011341:Probucol / Q000627:therapeutic use*; D011507:Proteinuria / Q000188:drug therapy* / Q000209:etiology; D011692:Puromycin Aminonucleoside; D051381:Rats
D011692:Puromycin Aminonucleoside; D011341:Probucol